BioNTech reports Q3 EPS EUR 6.98 vs. EUR 12.35 last year

Reports Q3 revenues EUR 3.46B vs. EUR 6.09B last year. "I would like to thank our growing BioNTech team for their outstanding performance in the first nine months of 2022 which allowed us to be the first company to provide access to a BA.4/BA.5 variant adapted bivalent vaccine at an unprecedented speed. We are working to leverage this experience and apply the lessons learned from the development of Omicron-adapted vaccines to other disease areas and product candidates," said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "The next chapter of BioNTech’s evolution is becoming tangible; we continue to expand our COVID-19 vaccine and infectious disease portfolio and advance our oncology pipeline. We reaffirm our commitment to improving the health of people worldwide by developing immunotherapies that utilize the full potential of the immune system to fight cancer, infectious and other serious diseases."